Physician profile
Stephen L Riso
NPI 1639498959
$969.97
in general payments reported to CMS, 2019-2025
14 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.49 · 2020: $33.98 · 2021: $175 · 2022: $331 · 2023: $18.33 · 2024: $218 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $283.98 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $166.33 | 2024-2025 | Verquvo, Capvaxive |
| Insmed, INC. | $115.89 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.74 | 2022-2024 | Jardiance |
| Amgen INC. | $51.31 | 2022-2025 | Repatha |
| Abbott Laboratories | $43.72 | 2021-2024 | Freestyle Libre 3 |
| Aquestive Therapeutics, INC. | $36.86 | 2019 | |
| Merz Pharmaceuticals, LLC | $33.30 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $26.60 | 2024 | Rexulti |
| Csl Behring | $25.76 | 2021 | |
| Genzyme Corporation | $24.32 | 2019 | |
| Alnylam Pharmaceuticals INC. | $20.20 | 2019 | |
| Urovant Sciences INC | $19.85 | 2022 | |
| Pfizer INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Riso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.